Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidemiological studies in mucus hypersecretion.

Jørgen Vestbo1

  • 1Department of Respiratory Medicine, Hvidovre University Hospital, Kettegaard Alle 30, Hvidore, DK-2650, Denmark.

Novartis Foundation Symposium
|February 6, 2003
PubMed
Summary

Mucus hypersecretion is a significant risk factor in respiratory diseases like COPD and asthma. It is linked to accelerated lung function decline, increased hospital admissions, and higher mortality rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

American journal of respiratory and critical care medicine·2026
Same author

COPD Trial Evidence Comes From a Narrow Slice of the World: A Population Representativeness Analysis.

Chest·2026
Same author

Prevalence of respiratory viruses in stable and acute asthma: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.

Expert review of vaccines·2026
Same author

Plasma growth differentiation factor-15 is associated with cardiovascular events in patients hospitalized for acute exacerbation of COPD.

Scientific reports·2026

Area of Science:

  • Pulmonary Medicine
  • Epidemiology

Background:

  • Respiratory mucus, assessed via questionnaires on cough and phlegm, is central to respiratory epidemiology.
  • The role of mucus hypersecretion in chronic obstructive pulmonary disease (COPD) has been debated, shifting from a key factor to an 'innocent disorder' and now back to a recognized risk factor.

Purpose of the Study:

  • To review the evolving understanding of mucus hypersecretion's impact on respiratory health.
  • To highlight its significance in COPD and asthma epidemiology.

Main Methods:

  • Review of epidemiological studies and literature on respiratory mucus.
  • Analysis of data concerning mucus hypersecretion, lung function decline, hospital admissions, and mortality in COPD and asthma cohorts.

Main Results:

  • Early occupational studies found no link between mucus hypersecretion and lung function decline, but later general population studies show a significant effect.
  • Chronic mucus hypersecretion is associated with increased hospital admissions, potentially due to higher risks of lower respiratory tract infections.
  • In severe COPD, mucus presence correlates with increased mortality.
  • In asthma, mucus hypersecretion may signal poor disease control, leading to faster lung function decline and increased mortality.

Conclusions:

  • Mucus hypersecretion is a critical factor in respiratory disease progression and outcomes.
  • It is a risk factor for accelerated lung function decline, hospitalizations, and mortality in COPD and asthma.
  • Re-evaluation of mucus hypersecretion's role is crucial for understanding and managing these conditions.

Related Experiment Videos